Zyrova C 20mg/75mg Capsule is a combination medication containing Rosuvastatin 20mg and Clopidogrel 75mg, indicated for the management of cardiovascular conditions requiring both lipid-lowering and antiplatelet therapy. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C), thereby aiding in the prevention of atherosclerosis and related cardiovascular events. Clopidogrel, an antiplatelet agent, inhibits platelet aggregation by irreversibly blocking the P2Y12 component of ADP receptors on platelet surfaces, reducing the risk of thrombotic events such as myocardial infarction, stroke, and peripheral arterial disease. The combined formulation is particularly beneficial in patients with established coronary artery disease, recent acute coronary syndrome, or those undergoing percutaneous coronary intervention requiring dual therapy. Zyrova C should be administered under medical supervision with regular monitoring of lipid profiles, liver function tests, and hematological parameters to detect potential adverse effects such as myopathy, bleeding, or hepatic dysfunction. Contraindications include active bleeding, hypersensitivity to either component, and severe hepatic impairment. Patient adherence and lifestyle modifications remain essential adjuncts to optimize therapeutic outcomes with Zyrova C.